Commentary: Can the new synthetic adeno-associated virus vector deliver the promise of cardiac gene therapy?

Abstract

The new synthetic adenoassociated virus vector Anc80L65 has superior gene transfer efficiency over the adeno-associated virus 9 vector in rat hearts, but other obstacles remain.